Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Long-Term Investments (2017 - 2025)

Anaptysbio (ANAB) has disclosed Long-Term Investments for 9 consecutive years, with $7.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Investments fell 72.42% year-over-year to $7.7 million, compared with a TTM value of $7.7 million through Sep 2025, down 72.42%, and an annual FY2024 reading of $35.5 million, up 31.24% over the prior year.
  • Long-Term Investments was $7.7 million for Q3 2025 at Anaptysbio, down from $28.0 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $147.5 million in Q3 2022 and bottomed at $5.5 million in Q2 2021.
  • Average Long-Term Investments over 5 years is $54.1 million, with a median of $40.2 million recorded in 2023.
  • The sharpest move saw Long-Term Investments tumbled 85.95% in 2021, then soared 2270.26% in 2022.
  • Year by year, Long-Term Investments stood at $67.1 million in 2021, then soared by 113.03% to $142.9 million in 2022, then tumbled by 81.09% to $27.0 million in 2023, then soared by 31.24% to $35.5 million in 2024, then plummeted by 78.3% to $7.7 million in 2025.
  • Business Quant data shows Long-Term Investments for ANAB at $7.7 million in Q3 2025, $28.0 million in Q2 2025, and $43.0 million in Q1 2025.